There’s nothing like beginning-of-the-year price increases to turn up the heat on the prescription drug pricing debate in the U.S. This year is no exception. Citing a mean price increase of 5.1% on brand drugs in the first 25 days of 2022, 13 Democratic lawmakers, led by Sen. Elizabeth Warren (D-Mass.), wrote this week to Steven Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America, demanding an explanation for those hikes.
A study by researchers led by David James from the University of Sydney showcases the diversity in metabolic responses observed across different mouse strains exposed to two different diets that demonstrates the heritability of metabolic traits.
The discovery of a hormone regulating blood glucose levels independently of insulin could lead to the development of new diabetes therapies and open up promising new avenues in metabolism research, according to a study led by researchers at the Salk Institute for Biological Studies.
After delaying it twice, the U.S. Department of Health and Human Services (HHS) is proposing to rescind a Trump-era rule that would have given certain low-income patients insulin and injectable epinephrine products at the steeply discounted 340B rate.
“We’re launching at the right time,” said Frank Sanders, president of Zealand Pharma A/S’s business in the U.S., in the wake of clearance granted by the FDA for the Copenhagen, Denmark-based firm’s glucagon analogue Zegalogue (dasiglucagon) in severe hypoglycemia.
A consequence of one of President Joe Biden’s first executive orders (EOs) is that some low-income patients may have to wait at least two more months to get the out-of-pocket relief they were promised for insulin and injectable epinephrine.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production. The investigators reported their results in the Sept. 2, 2020, edition of Science Translational Medicine.
An Australian study led by University of Melbourne scientists has identified a previously unknown role for the hepatokine, sparc-related modular calcium-binding protein 1 (SMOC1), in suppressing hepatic glucose production. The investigators reported their results in the Sept. 2, 2020, edition of Science Translational Medicine.
Investigators are working to develop electrogenetic devices that use remote-controlled electrical stimulation to elicit specific behaviors in engineered cells. They are following in the footsteps of optogenetics, which use specific wavelengths of light to control cell function remotely. A new study published in Science used such a device paired with encapsulated, engineered human pancreatic beta cells to express enough insulin to restore normal glycemic levels in mice models of diabetes.
